Rethinking cancer therapy for the benefit of all
Over the past five decades the cost of cancer therapy has increased and poses a financial burden for health care institutions and patients alike.
Oncolodyne’s drug reprofiling or repurposing strategy offers significant advantages over conventional drug development approach: Cost effective development, existing epidemiological and population level knowledge, known side effects and a fast track to clinical trials. Our drug discovery pipeline is deeply rooted in biological and epidemiological evidence and validated in robust electrophysiological, intracellular and in vivo models.